Propafenone‐ vs . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure

Documenti analoghi

• Population pharmacokinetic analysis of the interaction of digoxin with N‐desethylamiodarone in patients with atrial fibrillation and heart failure
  di: Toshinori Hirai, et al.
  Pubblicazione: (2025)
• Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation
  di: Muhan Yeo, et al.
  Pubblicazione: (2024)
• Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation
  di: Alisha Niskala, et al.
  Pubblicazione: (2024)
• The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients
  di: Dávid Nagy, et al.
  Pubblicazione: (2025)
• Clinical outcomes associated with ACE inhibitors and ARBs use in adults older than 85 years who recovered from dialysis‐requiring acute kidney injury
  di: Jui‐Yi Chen, et al.
  Pubblicazione: (2025)